Wire · opportunities
FDA approves Lytenava for wet AMD
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 July 2026 · Fusion42 review
The FDA has approved Lytenava, the first ophthalmic formulation of bevacizumab specifically designed for intravitreal injection to treat wet AMD. The drug carries 12 years of reference product exclusivity and is expected to launch commercially before end of 2026.
This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.
◆ ◆ The Wire takeaway
For 20 years, retina specialists have been injecting a cancer drug into the eye because no ophthalmic version existed. Lytenava closes that gap with 12 years of exclusivity, which means compounders, rival anti-VEGF makers, and anyone selling adjacent diagnostics or delivery devices just lost a large pool of off-label custom. If you're in retinal imaging, injection systems, or patient monitoring in AMD, your customer base now has a purpose-built alternative.
◆ Related on Wire
◆ Topics